GlassScriptPhysician profile
Asad Pervez
NPI 1992122063
$2,538.82
in general payments reported to CMS, 2019-2025
17 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $17.08 · 2021: $31.80 · 2022: $70.82 · 2023: $360 · 2024: $1,323 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040 · Travel and Lodging: $874 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.89 |
| Travel and Lodging | $873.77 |
| Education | $156.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $1,154.97 | 2024 | |
| Medtronic, INC. | $263.39 | 2023-2025 | Gi Genius, Endoflip |
| Abbvie INC. | $244.95 | 2019-2025 | |
| Janssen Biotech, INC. | $170.63 | 2024-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $132.58 | 2019-2023 | Cre Pro |
| Nestle Healthcare Nutrition INC. | $124.12 | 2022-2023 | |
| Daiichi Sankyo INC. | $118.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.46 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.65 | 2023 | Xifaxan |
| Pfizer INC. | $33.50 | 2024-2025 | |
| Genzyme Corporation | $33.12 | 2024 | |
| Braintree Laboratories, INC. | $31.37 | 2023-2025 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $28.47 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $26.66 | 2023 | |
| Mallinckrodt Hospital Products INC. | $24.44 | 2023 | Terlivaz |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.12 | 2025 | Amplatzer Amulet |
| E.R. Squibb & Sons, L.L.C. | $14.82 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asad Pervez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.